High-risk clinical stage I NSGCT: the case for RPLND.
BACKGROUND
High-risk clinical stage I NSGCT patients are at significant risk of harbouring occult metastatic disease. In these patients, treatment options consist of retroperitoneal lymph node dissection (RPLND) or two cycles of primary BEP chemotherapy. Both these options provide a nearly 100% cure rate.


METHODS
We review the rationale for both treatments.


CONCLUSIONS
Advantages of RPLND include high cure rate with single modality therapy eliminating the need for chemotherapy with its attendant long-term toxicities in the majority of patients.
Morash
Christopher
C
Division of Urology, Department of Surgery, B3 Urology, The Ottawa Hospital, Ottawa, ON, K1Y 4E9, Canada. cmorash@ottawahospital.on.ca
Cagiannos
Ilias
I
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D008197:Lymph Node Excision / Q000379:methods*; D008297:Male; D009362:Neoplasm Metastasis / Q000517:prevention & control; D009367:Neoplasm Staging; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy / Q000601:surgery*; D012187:Retroperitoneal Space; D012307:Risk Factors; D013736:Testicular Neoplasms / Q000188:drug therapy / Q000601:surgery*
D001761:Bleomycin; D005047:Etoposide; D002945:Cisplatin